A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 28, 2019

Primary Completion Date

July 30, 2020

Study Completion Date

January 31, 2022

Conditions
Metastatic Prostatic Adenocarcinoma
Interventions
DRUG

Opdivo Injectable Product

"Opdivo (nivolumab): PD-1 inhibitor antibody~Injectable 10mg/mL, only 1 mL injected."

DRUG

Yervoy Injectable Product

"Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 1 mL injected."

DRUG

Cytoxan

"Cytoxan (cyclophosphamide): Chemotherapy agent~Both Injectable and Oral low dose:~Injectable 250mg/m2, only 1 mL injected. Oral low dose cyclophosphamide: option of either 50mg once daily pill or 25mg twice daily pill for two weeks on, then two weeks off, then two weeks on again."

PROCEDURE

Cryosurgical freezing (cryosurgery)

Cryosurgery, also known as cryoablation, for prostate cancer works by freezing the cancer cells inside the prostate gland. Cryoablation will release intact antigens to prime the immune system.

Trial Locations (2)

48307

Ascension Providence Rochester Hospital, Rochester

93534

Antelope Valley Urology & Incontinence, Lancaster

All Listed Sponsors
lead

Rampart Health, L.L.C.

INDUSTRY

NCT04090775 - A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma | Biotech Hunter | Biotech Hunter